These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2120060)

  • 21. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
    Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
    Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
    Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
    Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of S-ofloxacin.
    Neu HC; Chin NX
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1105-7. PubMed ID: 2506805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
    Barry AL; Fuchs PC
    Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969).
    Espinoza AM; Chin NX; Novelli A; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):663-70. PubMed ID: 3293524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group.
    Jones RN; Hoban DJ
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):49-56. PubMed ID: 8026157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study.
    Song A; McCulley TJ; Lam BL; Feuer WJ; Miller D; Alfonso EC
    Am J Ophthalmol; 2001 Jun; 131(6):795-6. PubMed ID: 11384579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.
    Bauernfeind A
    J Antimicrob Chemother; 1993 Apr; 31(4):505-22. PubMed ID: 7605398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro activity of the new fluoroquinolone CP-99,219.
    Neu HC; Chin NX
    Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
    Wise R; Andrews JM; Brenwald N
    J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa.
    Kowalski RP; Pandya AN; Karenchak LM; Romanowski EG; Husted RC; Ritterband DC; Shah MK; Gordon YJ
    Ophthalmology; 2001 Oct; 108(10):1826-9. PubMed ID: 11581056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin?: Report from The SENTRY Antimicrobial Surveillance Program (1997-99).
    Jones RN; Pfaller MA;
    Diagn Microbiol Infect Dis; 2001 Apr; 39(4):237-43. PubMed ID: 11404067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents.
    Hirschhorn L; Neu HC
    Chemotherapy; 1987; 33(1):28-39. PubMed ID: 3549179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
    Gu JW; Neu HC
    Antimicrob Agents Chemother; 1990 Feb; 34(2):189-95. PubMed ID: 2327765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone.
    Gooding BB; Jones RN
    Antimicrob Agents Chemother; 1993 Feb; 37(2):349-53. PubMed ID: 8043036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents.
    Wise R; Andrews JM; Ashby JP; Matthews RS
    Antimicrob Agents Chemother; 1988 May; 32(5):617-22. PubMed ID: 3134843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.